Genmab A/S (NASDAQ:GMAB) Releases Earnings Results, Beats Estimates By $0.29 EPS

Genmab A/S (NASDAQ:GMAB) announced its quarterly earnings data on Wednesday. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.29, Zacks reports. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. Genmab A/S updated its FY 2025 guidance to EPS.

Genmab A/S Stock Up 4.2 %

Shares of NASDAQ GMAB opened at $19.69 on Thursday. The firm has a market cap of $13.03 billion, a price-to-earnings ratio of 19.12, a price-to-earnings-growth ratio of 0.54 and a beta of 0.96. Genmab A/S has a 52-week low of $18.64 and a 52-week high of $31.88. The company’s 50-day simple moving average is $20.68 and its 200-day simple moving average is $23.21.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on GMAB shares. BMO Capital Markets reaffirmed an “outperform” rating and issued a $48.00 price target (up from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. Sanford C. Bernstein raised Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research report on Thursday, January 23rd. BNP Paribas raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday. Finally, Leerink Partners raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 target price on the stock in a research note on Thursday. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, Genmab A/S currently has a consensus rating of “Moderate Buy” and a consensus price target of $42.17.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.